Sugammadex Clinical Trial Issues Still Causing Trouble For Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
After FDA abruptly cancelled an advisory committee meeting on the anesthesia injection product in July to review trial site inspection results for a hypersensitivity study, it issues a “complete response” letter indicating site “operational” concerns.
You may also be interested in...
Ground Hog Day For Merck: FDA Again Cancels Sugammadex Advisory Committee Review
FDA is conducting additional inspections of the site of a hypersensitivity study the agency requested in 2008; concerns about the study derailed a committee review in 2013.
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.
Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.